Proposal for a sole supply arrangement for fentanyl patches
8 July 2013
PHARMAC is seeking feedback on a proposal to list a new brand of fentanyl patches, Fentanyl Sandoz, under a sole supply arrangement with Novartis New Zealand Limited.
This proposal arose from a request for proposals (RFP) issued by PHARMAC in which pharmaceutical companies were invited to compete to be the sole subsidised supplier of fentanyl patches.
This proposal would provide savings to the Combined Pharmaceutical Budget and would result in a change in the funded brand of fentanyl patches. In summary:
- Fentanyl Sandoz would be listed in the Pharmaceutical Schedule as soon as possible following Medsafe registration;
- from the date of listing Fentanyl Sandoz, the currently funded brand of fentanyl patches, Mylan Fentanyl Patch, would remain fully subsidised for 6 months, after which time Mylan Fentanyl Patch would be delisted;
- following the delisting of Mylan Fentanyl Patch, Fentanyl Sandoz would be the only subsidised brand of fentanyl patches until 30 June 2016.
It is anticipated that if this proposal is approved it would be implemented towards the end of this year or early next year.
Further details of the proposal can be found following.
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5:00 pm Monday 22 July 2013 to:
Therapeutic Group Manager
Fax: 04 460 4995
Post: PO Box 10 254, Wellington 6143
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Last updated: 3 March 2016